PMID- 18157602
OWN - NLM
STAT- MEDLINE
DCOM- 20080416
LR  - 20181113
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 119
IP  - 23-24
DP  - 2007
TI  - [Small cell lung cancer].
PG  - 697-710
AB  - With about 20% of all lung cancers small cell lung cancer (SCLC) represents a 
      major subset of this entity. Although therapeutic improvements did not receive as 
      much attention as in non small cell lung cancer (NSCLC), many small steps of 
      clinical progress have been achieved within the last 20 years. An optimal 
      treatment should be based on an interdisciplinary treatment plan. The standard 
      treatment in localized stages represents combined radiation and chemotherapy. 
      Cisplatin and etoposide are in this concern considered as a gold standard. 
      3D-planned conformal radiotherapy should start as early as possible and should be 
      applied concomitantly to chemotherapy and in certain cases even in a 
      hyperfractionated treatment protocol. In very early stages surgical resection 
      could be an option in selected cases. In advanced stages a platinum-based doublet 
      offers high response rates. As already established in limited disease 
      prophylactic cranial irradiation is now also indicated in extensive disease in 
      case of any tumor remission. In the second line treatment and in patients with 
      reduced performance status topotecan is recommended. Similar as in NSCLC 
      pemetrexed might become an alternative treatment option in the second line 
      setting. In the field of new targeted therapies bevacizumab achieved the most 
      promising results. The present review highlights historical milestones and 
      up-to-date trends in radiotherapy, chemotherapy and surgery. Furthermore, the 
      role of experimental strategies and the management of certain special clinical 
      situations are discussed.
FAU - Hoschek, Stefan
AU  - Hoschek S
AD  - Landeskrankenhaus Hochzirl, Abteilung fur Innere Medizin, Hochzirl, Osterreich.
FAU - Hoschek-Risslegger, Ursula
AU  - Hoschek-Risslegger U
FAU - Fiegl, Michael
AU  - Fiegl M
FAU - Zabernigg, August
AU  - Zabernigg A
FAU - Pall, Georg
AU  - Pall G
FAU - Auberger, Thomas
AU  - Auberger T
FAU - Gunsilius, Eberhard
AU  - Gunsilius E
FAU - Schmid, Thomas
AU  - Schmid T
FAU - Jamnig, Herbert
AU  - Jamnig H
FAU - Hilbe, Wolfgang
AU  - Hilbe W
CN  - Tiroler Arbeitskreis fur Onkologie TAKO
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Das kleinzellige Bronchialkarzinom.
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
SB  - IM
MH  - Carcinoma, Small Cell/*diagnosis/*therapy
MH  - Drug Therapy/*trends
MH  - Humans
MH  - Lung Neoplasms/*diagnosis/*therapy
MH  - Practice Patterns, Physicians'/trends
MH  - Radiotherapy/*trends
RF  - 121
EDAT- 2007/12/25 09:00
MHDA- 2008/04/17 09:00
CRDT- 2007/12/25 09:00
PHST- 2007/08/01 00:00 [received]
PHST- 2007/11/15 00:00 [accepted]
PHST- 2007/12/25 09:00 [pubmed]
PHST- 2008/04/17 09:00 [medline]
PHST- 2007/12/25 09:00 [entrez]
AID - 10.1007/s00508-007-0913-1 [doi]
PST - ppublish
SO  - Wien Klin Wochenschr. 2007;119(23-24):697-710. doi: 10.1007/s00508-007-0913-1.